# US 2024/0197697 A1 · Rifabutin treatment methods, uses, and compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197697 A1
- Document ID: US20240197697A1
- Status: Published application
- Kind: A1
- Application number: 18/435,221
- Filed: 2024-02-07
- Published: 2024-06-20
- Earliest claimed: 2019-09-18
- Assignees: Bioversys AG
- Applicants: Bioversys AG
- Inventors: Glenn E. Dale; Sergio Lociuro; Marc Gitzinger; Stefano Biondi; Marilyne Bourotte
- Web page: https://patentgrep.com/patent/US20240197697A1

## CPC

- A61K 31/438: The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention provides formulations containing highly concentrated solutions of rifabutin and methods of making such formulations. The invention also provides methods of using such formulations to treat a bacterial infection in a subject.

## Claims

### Claim 1

A rifabutin formulation produced from a rifabutin powder in the presence of an acid, water, and a solvent suitable to promote dissolution of the rifabutin.

### Claim 2 (depends on 1)

The formulation of claim 1, wherein the ratio of rifabutin to solvent w/v is about 1:2.

### Claim 3 (depends on 1)

The formulation of claim 1, wherein the solvent is selected from the group consisting of: PEG, propylene glycol, NMP, ethanol, DMA, transcutol HP, and dimethyl isosorbide (DMI).

### Claim 4 (depends on 3)

The formulation of claim 3, wherein the solvent is DMI or trascutol HP.

### Claim 5 (depends on 1)

The formulation of claim 1, wherein the solvent to water ratio v/v is from about 1:1 to about 1:2.

### Claim 6 (depends on 1)

The formulation of claim 1, wherein the acid is selected from the group consisting of: hydrochloric, methanesulfonic, phosphoric, L-tartaric, D-glucuronic, L-malic, D-gluconic, L-lactic, acetic and L-aspartic.

### Claim 7 (depends on 6)

The formulation of claim 6, wherein the acid is acetic acid or D-glucuronic acid.

### Claim 8 (depends on 1)

The formulation of claim 1, wherein the rifabutin to acid molar ratio is about 1:1.

### Claim 9 (depends on 1)

The formulation of claim 1, wherein the formulation is diluted in order to produce a composition suitable for a desired route of administration.

### Claim 10

A method of preparing a formulation of rifabutin, the method comprising:
preparing a solution comprising a solvent, water and an acid; and
adding said solution to rifabutin powder, thereby causing the rifabutin to dissolve in the solution.

### Claim 11 (depends on 10)

The method of claim 10, wherein the solvent is selected from DMI and tanscutol HP.

### Claim 12 (depends on 10)

The method of claim 10, wherein the acid is selected from acetic acid and D-glucuronic acid.

### Claim 13

A method of preparing a formulation of rifabutin, the method comprising:
preparing a solution comprising water and an acid; and
adding said solution to a rifabutin solution in a solvent, thereby producing an aqueous rifabutin formulation.

### Claim 14 (depends on 13)

The method of claim 13, wherein the solvent is selected from DMI and tanscutol HP.

### Claim 15 (depends on 13)

The method of claim 13, wherein the acid is selected from acetic acid or D-glucuronic acid.

### Claim 16

A method of treating a bacterial infection in a subject, the method comprising administering a therapeutically effective amount of rifabutin in an injectable formulation or by inhalation.
